文献速递神经肌肉病

散发性肌萎缩侧索硬化患者脑脊液Aβ、Tau、轴突、突触、胶质、神经及炎症生物标志物研究

CSF Aβ, Tau, Axonal, Synaptic, Glial, Neural, and Inflammatory Biomarkers in Patients With Sporadic Amyotrophic Lateral Sclerosis.
PubMed 文献 · Neurology · 2025-09-11

本研究在山东大学齐鲁医院开展观察性研究,检测180名受试者(109例散发性ALS患者、30例疾病对照、41例健康对照)脑脊液中约200种蛋白,发现ALS患者多种脑脊液蛋白显著改变,并构建3蛋白组合(CHIT1、N-CDase、PDGF-R-alpha)区分ALS与疾病对照,在原队列AUC为0.927(95%CI 0.883-0.971),在独立验证队列AUC为0.912(95%CI 0.841-0.985)。

要点

  • ALS患者脑脊液神经丝轻链、壳三糖苷酶(CHIT1)等56种蛋白显著升高,Aβ40、Aβ42和GAP43显著降低。
  • 3蛋白脑脊液组合(CHIT1、N-CDase、PDGF-R-alpha)可有效区分散发性ALS与疾病对照。
  • 该组合诊断性能在原队列和独立验证队列中均得到验证,但样本量较小且缺乏多重比较校正。

核心结论

  • 散发性ALS患者脑脊液存在轴突、胶质、突触及Aβ相关蛋白的广泛改变,支持混合性共病理机制。
  • 基于CHIT1、N-CDase和PDGF-R-alpha的3蛋白脑脊液组合可有效区分ALS与疾病对照,并在独立队列中验证。

研究设计与样本

  • 观察性研究,在山东大学齐鲁医院开展,采用邻位延伸分析、单分子阵列和ELISA检测脑脊液中约200种蛋白。
  • 共纳入180名参与者:109例散发性ALS患者(平均年龄56.7±11.9岁,58.7%男性)、30例疾病对照(56.9±12.6岁,56.7%男性)、41例健康对照(57.1±12.4岁,63.4%男性)。
  • 应用Xtreme梯度提升和逻辑回归模型构建脑脊液蛋白组合,并在独立队列中验证诊断性能。

主要发现

  • 与健康对照相比,ALS患者脑脊液神经丝轻链、壳三糖苷酶(CHIT1)等几丁质酶蛋白及另外55种蛋白水平显著升高。
  • ALS患者脑脊液Aβ40、Aβ42和GAP43水平显著低于健康对照。
  • 3蛋白组合(CHIT1、N-CDase、PDGF-R-alpha)区分ALS与疾病对照的AUC在原队列为0.927(95%CI 0.883-0.971),在验证队列为0.912(95%CI 0.841-0.985)。

关键数值与推荐

  • 3蛋白脑脊液组合(CHIT1、N-CDase、PDGF-R-alpha)区分ALS与疾病对照:原队列AUC 0.927(95%CI 0.883-0.971)。
  • 同一组合在独立验证队列AUC为0.912(95%CI 0.841-0.985)。

临床怎么用

  • 该3蛋白脑脊液组合有望作为辅助散发性ALS与疾病对照鉴别诊断的生物标志物,但需在更大规模多中心研究中进一步验证后方可用于临床。
  • 脑脊液神经丝轻链、CHIT1升高及Aβ40、Aβ42、GAP43降低可作为ALS病理生理改变的参考指标。

局限性

  • 队列相对较小。
  • 未进行多重比较校正。
  • 需要在更大规模、多中心研究中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder with multifactorial pathophysiologic mechanisms, yet reliable CSF biomarkers for the diagnosis of ALS are lacking. The aim of this study was to systematically identify CSF protein alterations in patients with sporadic ALS and to develop an effective CSF protein panel to aid in ALS diagnosis. METHODS: This observational study was conducted at Qilu Hospital, Cheeloo College of Medicine, Shandong University. Using proximity extension assay, single-molecule array, and ELISA, approximately 200 proteins involved in different pathogenic events, including axonal damage, neuronal damage, glial responses, synaptic dysfunction, β-amyloid (Aβ) pathology, tau pathology, and neuroinflammation, were measured in the CSF. Moreover, Xtreme gradient boosting and logistic regression models were applied to develop a CSF protein panel to distinguish patients with sporadic ALS from disease controls (DCs), and the diagnostic performance was verified in an independent cohort. RESULTS: A total of 180 participants were included, comprising 109 patients with sporadic ALS (mean age 56.7 ± 11.9 years, 58.7% male), 30 DCs (56.9 ± 12.6 years, 56.7% male), and 41 healthy controls (HCs, 57.1 ± 12.4 years, 63.4% male). Compared with HCs, patients with ALS had significantly elevated CSF levels of neurofilament light chain, chitinase proteins including chitotriosidase (CHIT1), and 55 other proteins, whereas CSF Aβ40, Aβ42, and GAP43 levels were significantly lower. Moreover, we identified a 3-protein CSF panel (CHIT1, N-CDase, and PDGF-R-alpha) that effectively distinguished patients with ALS from DCs, achieving an area under the curve of 0.927 (95% CI 0.883-0.971) in the original cohort and 0.912 (95% CI 0.841-0.985) in the replication cohort. DISCUSSION: Using a combined approach, we comprehensively investigated CSF protein alterations in a cohort of newly diagnosed patients with ALS and provided further in vivo evidence supporting the presence of mixed copathologies in patients with ALS. Moreover, we developed a 3-protein CSF biomarker panel that effectively distinguished patients with ALS from DCs and validated its performance in an independent cohort. However, considering the relatively small cohort and lack of multiple comparison adjustments, further validation in larger, multicenter studies is warranted.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Chen Y, Sun S, Bai Z, et al. CSF Aβ, Tau, Axonal, Synaptic, Glial, Neural, and Inflammatory Biomarkers in Patients With Sporadic Amyotrophic Lateral Sclerosis. Neurology. 2025. PMID: 40934454. doi:10.1212/WNL.0000000000213914

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。